To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2397 | Gsk557296 |
Novel highly potent and selective non-peptide oxytocin receptor antagonist
More description
|
|
| DCC2396 | Gsk466317a |
Novel selective inhibitor of G protein-coupled receptor kinase 2 (GRK2)
More description
|
|
| DCC2395 | Gsk452 |
Novel, Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitor
More description
|
|
| DCC2394 | Gsk41364a |
Novel specific inhibitor of polo-like kinase 1 (PLK-1), inducing cell death by causing cell cycle arrest at G2/M phase by competing with the ATP binding site of PLK-1 thus leading to apoptosis
More description
|
|
| DCC2393 | Gsk4028 |
Negative control for GSK4027
More description
|
|
| DCC2392 | Gsk-3ß/hdac Inhibitor C11 |
First-in-Class GSK-3β/HDAC Dual Inhibitor as a Disease-Modifying Agent To Combat Alzheimer’s Disease
More description
|
|
| DCC2391 | Gsk3-in-40 |
Potent and irreversible inhibitor of GSK3
More description
|
|
| DCC2389 | Gsk3i Xv |
Novel highly potent cell-permeable, reversible, ATP-competitive inhibitor of GSK-3 (IC50 = 0.4 and 0.6 nM for GSK-3α and GSK-3β, respectively)
More description
|
|
| DCC2388 | Gsk3830052 |
Novel DNMT1-selective inhibitor (IC 50 = 0.11 ± 0.02 µM)
More description
|
|
| DCC2387 | Gsk366a |
Novel anti-TB agent against Mycobacterium tuberculosis and Mycobacterium bovis BCG, targeting MmpL3 and inhibiting EchA6
More description
|
|
| DCC2386 | Gsk360a |
Novel inhibitor of prolyl hydroxylase (PHD) domain-containing enzyme
More description
|
|
| DCC2385 | Gsk-354 |
Novel lysine specific histone demethylase 1 (LSD1) inhibitor, exhibiting high selectivity to LSD1 over MAOs
More description
|
|
| DCC2384 | Gsk334429 |
Novel selective non-imidazole histamine H 3 receptor antagonist
More description
|
|
| DCC2383 | Gsk3277329 |
Novel agonist of toll-like receptor 2 (TLR2), stimulating the release of G-CSF in activated THP-1 cells, peripheral blood mononuclear cells, and human umbilical vein endothelial cells
More description
|
|
| DCC2382 | Gsk3182571 |
Promiscuous kinase inhibitor, a close analog of CTx-0294885
More description
|
|
| DCC2381 | Gsk317354a |
Novel selective inhibitor of G protein-coupled receptor kinase 2 (GRK2)
More description
|
|
| DCC2380 | gsk314181a |
Potent and selective antagonist of P2X7 receptor
More description
|
|
| DCC2379 | Gsk3038548a |
Novel potent RORγ inverse agonist
More description
|
|
| DCC2378 | Gsk-3008348-n1-methyl |
Novel quaternized GSK-3008348 derivative, acting as a highly selective αvβ6 Integrin Inhibitor
More description
|
|
| DCC2377 | Gsk299115a |
Novel inhbitor of protein kinase GRK1/2/5 and PKA
More description
|
|
| DCC2376 | Gsk2838232 |
Novel human immune virus (HIV) maturation inhibitor
More description
|
|
| DCC2375 | Gsk-2807 |
Novel potent and selective, SAM-competitive inhibitor of SMYD3
More description
|
|
| DCC2374 | Gsk270822a |
Novel selective inhibitor of G protein-coupled receptor kinase 2 (GRK2)
More description
|
|
| DCC2373 | Gsk2565363c |
Betulin derivative as antitumor agent
More description
|
|
| DCC2372 | Gsk246053 |
Specific ATPase competitive kinesin-5 inhibitor
More description
|
|
| DCC2371 | Gsk-239512 |
Novel selective histamine H3 receptor antagonist
More description
|
|
| DCC2370 | Gsk237701a |
Novel I-kappa-B kinase-3 (IKK3) inhibitor
More description
|
|
| DCC2369 | Gsk2263167 |
Novel S1P1 receptor agonist
More description
|
|
| DCC2368 | Gsk2256294a |
Novel highly potent, reversible soluble epoxide hydrolase (sEH) inhibitor, exhibiting potent cell-based activity, a concentration-dependent inhibition of the conversion of 14,15-EET to 14,15-DHET, attenuating cigarette smoke-induced inflammation by both i
More description
|
|
| DCC2367 | Gsk223 |
Selective inhibitor of iE-DAP-stimulated IL-8 release via the NOD1 signaling pathway
More description
|
|